Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

t of blepharospasm, a neurological condition that, if untreated, can cause significant disability."

The first poster presented at the AAO meeting, titled "Dosing Profile of XEOMIN (incobotulinumtoxinA) During Long-Term, Open-Label Treatment of Benign Essential Blepharospasm," evaluated the repeat-dosing profile of XEOMIN for up to 48 weeks, including the inter-injection interval, during an open-label extension (OLEX) of the Phase III randomized, double-blind trial that evaluated XEOMIN versus placebo. Although the injection frequency varied during the OLEX and many participants received injections at less than 12-week intervals, the investigator-determined dosing profile of XEOMIN remained similar to the initial single-treatment study, which was based on prior treatment with Botox®. [PO440, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]

The second poster presented at the AAO meeting, titled "Adverse Event (AE) Profile of XEOMIN (incobotulinumtoxinA) in the Benign Essential Blepharospasm (BEB) Clinical Trials Program," assessed the AE profile of XEOMIN across two single-treatment trials (one versus placebo and one versus Botox®), as well as one repeat-treatment study (OLEX of the Phase III placebo-controlled study). [PO441, Oct. 24, 2011, 2 – 3:30 p.m. ET, Hall A1]

"Our community is always interested in learning more about XEOMIN and we are pleased to see these important data published in a prestigious journal and presented at the American Academy of Ophthalmology meeting. Merz has taken a strong interest in the blepharospasm community and the Company's commitment to educational programming is welcomed by the Benign Essential Blepharospasm Research Foundation," said Mary Lou (Koster) Thompson, BEBRF President.

About The Phase III Placebo-controlled Study and OLEXThe Phase III, randomized, placebo-controlled, double-blind study published in the journal Movement Disorders evaluated blepharospasm patients
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
(Date:8/29/2014)... 29, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... and consumables to the medical, research and veterinary markets, ... Chief Executive Officer, will present at the CL King ... Tuesday, September 9, 2014 at 12:30 p.m. ET. The ... Hotel in New York City . ...
(Date:8/29/2014)... August 29, 2014 Pixcelldata, the ... software has announced a major new deal with Dutch ... renowned pathology expert, Dr. Marius Nap . ... 26th European Congress of Pathology which is taking placing ... Arena, London where Pixcelldata will ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2
... Osteotech, Inc. (Nasdaq: OSTE ), a leader in the ... the Company,s first quarter ended March 31, 2010 financial ... May 10, 2010 .  The management team of Osteotech will host ... , at 9:00 a.m. (EDT) to discuss the Company,s ...
... Doctora Aliza, editor in chief of VidaySalud.com and expert health commentator for the ... Latino Legislative Caucus during a special Assembly floor session at the California Capitol ... , (Photo: ... "Doctor Aliza ...
Cached Medicine Technology:Osteotech Announces First Quarter 2010 Financial Results Release and Conference Call 2Latino Spirit Award For VidaySalud.com's Doctora Aliza 2
(Date:8/31/2014)... Mexico (PRWEB) August 31, 2014 On ... Rights friend-of-the-court brief in support of the New Mexico ... ruling that the New Mexico constitution contains a right ... Court of Appeals of the State of New Mexico). ... the brief: ADAPT, the American Association of People ...
(Date:8/31/2014)... 2014 Kicking blog MichaelHusted.com ... of Matt Nelson Kicking Academy on his role as ... a National Camp Series (NCS) Associate according to retired ... Nelson is another high quality to our NCS fraternity,” ... He is an outstanding pro prospect kicker, kicking ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The severity ... healthcare provider specializing in menopause is expert in ... expectations and relief from uncomfortable symptoms with the latest ... complementary therapies offer a variety of alternative treatments and ... While these treatment options may fall outside of what ...
(Date:8/30/2014)... 2014: A new method to predict the optimal ... presented at ESC Congress today by Dr Benjamin Dahan ... 350 AEDs located in public places for optimal prevention ... Dahan said: "Out of hospital cardiac arrest is a ... between 50 and 100 per 100 000 in the ...
(Date:8/30/2014)... According to the latest review on DailyGossip.org, this is the ... health. It seems that the method is so popular nowadays ... patients from all over the world. , The program ... will not only eliminate acne forever, but will also help ... program unique among other methods of curing candida is the ...
Breaking Medicine News(10 mins):Health News:Not Dead Yet and Six Other National Disability Groups Submit Friend-of-the-Court Brief in New Mexico Assisted Suicide Appeal 2Health News:Not Dead Yet and Six Other National Disability Groups Submit Friend-of-the-Court Brief in New Mexico Assisted Suicide Appeal 3Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 2Health News:MichaelHusted.com Features an Interview with Matt Nelson of Matt Nelson Kicking Academy on His Role as a Kicking Coach and on Becoming a National Camp Series Associate 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 2Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 3Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 4Health News:A Look at Complementary Therapies and Alternative Medicine for National Menopause Awareness Month 5Health News:New method predicts optimal number and location of AEDs 2Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2
... of Michigan evolutionary biologist Jianzhi "George" Zhang, has uncovered ... a sex determiner in honey bees. These novel inputs ... methods to breed honeybees, who are effective pollinators of ... findings of Zhang and collaborators are published in a ...
... to pain.In the study conducted on rats, the development// ... expression of that particular gene after a nerve injury ... of new painkillers. ,"Studies in volunteers showed ... variant that protects them from pain somewhat, and three ...
... disease is to be resumed and researchers from Southampton University ... ,The progress of the disease was supposed to be reversed ... the disease. But during the second phase of the trial, ... the study was brought to a halt for safety ...
... plastic and reconstructive surgeon has been given the go-ahead ... the Royal Free Hospital, London to select four patients ... College of Surgeons has called for caution with leading ... surgery promises to transform the lives of hundreds of ...
... implanted in 65,000 dogs in Shanghai to improve canine management ... at curbing// rabies in provinces of Yunnan and Shandong drew ... ID number. To access information about the dog - photo, ... have to access the ID number. ,Chip developer ...
... Gleneagles Hospitals has asked the West Bengal government for 10 ... here for setting up// a Rs.1.5 billion institute. ... research in the medical field, said V. Satyanarayana Reddy, CEO, ... the government to identify and hand over a site for ...
Cached Medicine News:Health News:Breeding success by delving into the honey bee sex gene 2Health News:Breeding success by delving into the honey bee sex gene 3Health News:Gene determines pain threshold... 2Health News:Alzheimer's Vaccine- A Realistic Prospect 2Health News:Green Signal given to Full-Face Transplants 2Health News:Green Signal given to Full-Face Transplants 3